We shouldn’t let government favoritism and wealthy individuals determine access to affordable medicine.

Conflict at Louisiana Pharmacy Benefit Manager Meeting

Last month, the Louisiana Pharmacy Benefit Manager Oversight Advisory Committee held a meeting that raised eyebrows—particularly due to one attendee’s notable conflict of interest. Dr. Alex Osimyansky, who leads the Cost Plus Drug Company backed by Mark Cuban, was invited to inform the committee about pharmacy benefit managers (PBMs). However, his company competes directly with these entities. To complicate matters, representatives from PBMs were not included in the discussion, turning what could have been an informative policy debate into more of a promotional showcase for a single competitor, ultimately not serving patients’ best interests.

Imbalanced Perspectives

Pharmacy benefit managers have long been in the crosshairs of critics. Mark Cuban, for instance, argues that PBMs create inefficient markets and lack transparency. This sentiment partly inspired the establishment of Osimyansky’s company, aimed at bypassing PBMs entirely.

During the hearing, Osimyansky shared his views on PBMs without any counterarguments. The absence of opposing voices resulted in a skewed perspective of the PBM system, which the council is responsible for overseeing.

This lack of balance presents two significant issues.

Firstly, the committee risks providing Congress with an incomplete understanding of how PBMs function—the services they offer, their strategies for negotiating lower drug prices, and other crucial details. With new PBM regulations already in place in Louisiana, the failure to hear from industry representatives could lead policymakers to base their conclusions on partial data instead of solid evidence.

Secondly, patients may face repercussions when public entities consider only one side of the narrative. PBMs play a critical role in managing drug insurance for millions of Americans, helping maintain access to affordable medications. Ignoring their perspectives could result in regulations that inadvertently raise costs or limit access, ultimately undermining the care intended for the people the state aims to protect.

Political Pressures

The broader political landscape in Louisiana adds further complexity. Governor Jeff Landry has been pushing for a complete ban on PBMs, a drastic step that would fundamentally alter how prescription coverage operates in the state. At the same time, Attorney General Liz Murrill has taken legal action against CVS, one of the largest PBMs in the country, raising concerns about the ramifications of such a ban.

This pattern reveals a troubling tendency: national figures often treat PBMs as adversaries rather than crucial partners. Such an approach shifts policymaking to a political battle, eroding public trust in fair regulation.

Call for Balanced Reforms

The PBM industry is resistant to reform; what they truly need is more transparency and accountability. However, effective policy starts with balance. The advisory committee should arrange a follow-up meeting where PBM representatives can sit at the same table as those from the Cost Plus Drug Company. The process needs to be open and transparent.

Ultimately, patients deserve policies informed by facts, not biased influences from wealthy backers. Regulations grounded in evidence rather than outrage are essential for protecting health, affordability, and public trust.